Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

June 30, 2018

Study Completion Date

August 31, 2018

Conditions
Carcinoma, Renal CellClear Cell Renal Cell Carcinoma
Interventions
DRUG

axitinib

Initial dose of axitinib: 5 mg orally twice a day. Maintenance dose of axitinib: Increase or decrease dose based on individual safety and tolerability. Dose range of axitinib: 2 to 10 mg twice a day.

Trial Locations (15)

Unknown

Demchenkova Marina Viktorovna, Irkutsk

Semenov Andrey Vladimirovich, Ivanovo

Mikhailova Nadezhda Vasilievna, Kazan'

Eskerov Kurban Abdulmutalibovich, Kirov

Zukov Ruslan Aleksandrovich, Krasnoyarsk

Ovchinnikova Elena Georgievna, Nizhny Novgorod

Guseva Irina Vasilievna, Penza

Vladimirova Lyubov Yur'evna, Rostov-on-Don

Zolotoreva Tatiana Gennadievna, Samara

Katkov Alexey Aleksandrovich, Saratov

Ivannikov Andrey Andreyevich, Tambov

Usynin Evgeny Anatolievich, Tomsk

Evstegneyeva Irina Vladimirovna, Tver'

Khmelevsky Andrey Anatolievich, Ufa

Gurina Ludmila Ivanovna, Vladivostok

All Listed Sponsors
lead

Kidney Cancer Research Bureau

OTHER

NCT02700568 - Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors | Biotech Hunter | Biotech Hunter